Paperpal Prime Logo

Clinical Genitourinary Cancer : Impact Factor & More

eISSN: 1938-0682pISSN: 1558-7673

Aims and Scope of Clinical Genitourinary Cancer

Clinical Genitourinary Cancer is a peer-reviewed medical journal published by Elsevier, and previously by CIG Media Group (Cancer Information Group). The journal publishes articles on detection, diagnosis, prevention, and treatment of genitourinary cancers. The main emphasis is on recent scientific developments in all areas related to genitourinary cancers. The journal was previously published as Clinical Prostate Cancer through September 2005. Less

Key Metrics

CiteScore
5.5
Impact Factor
< 5
SJR
Q2Urology
SNIP
0.97
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Clinical Genitourinary Cancer

Clinical Genitourinary Cancer Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • SJR SJR
Overview
Publisher CIG MEDIA GROUP, LP
Language English
Frequency Bi-monthly
General Details
LanguageEnglish
FrequencyBi-monthly
Publication Start Year2002
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Clinical Genitourinary Cancer ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Clinical Genitourinary Cancer

A Real-World Prospective Study of Comprehensive Genomic Testing in Patients With Metastatic Castration-Resistant Prostate Cancer.
  • 1 Aug 2026
  • Clinical genitourinary cancer
Targeting HER2 in Urothelial Carcinoma: Why Histologic Subtypes and Divergent Histologies Matter.
  • 1 Aug 2026
  • Clinical genitourinary cancer
Corrigendum to "Urinary Exosomal miR-17-5p Accelerates Bladder Cancer Invasion by Repressing its Target Gene ARID4B and Regulating the Immune Microenvironment" [Clinical Genitourinary Cancer 22/2 (2024) 569-579.e1
  • 1 Aug 2026
  • Clinical genitourinary cancer
Real-World Efficacy and Safety of Frontline Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Study and Review of the Literature.
  • 1 Aug 2026
  • Clinical genitourinary cancer
Toward Interpretable Machine Learning Models for Grading Prostate Cancer: A Multicenter Development and Validation Study.
  • 1 Aug 2026
  • Clinical genitourinary cancer
Robust Meta-Analysis of a Clinical Cell-Cycle Risk (CCR) Score Demonstrates Broadly Applicable Metastasis and Disease-Specific Mortality Risk Stratification in Men With Localized Prostate Cancer.
  • 1 Aug 2026
  • Clinical genitourinary cancer
A Real-World Prospective Study of Comprehensive Genomic Testing in Patients With Metastatic Castration-Resistant Prostate Cancer.
  • 1 Aug 2026
  • Clinical genitourinary cancer
Targeting HER2 in Urothelial Carcinoma: Why Histologic Subtypes and Divergent Histologies Matter.
  • 1 Aug 2026
  • Clinical genitourinary cancer
Corrigendum to "Urinary Exosomal miR-17-5p Accelerates Bladder Cancer Invasion by Repressing its Target Gene ARID4B and Regulating the Immune Microenvironment" [Clinical Genitourinary Cancer 22/2 (2024) 569-579.e1
  • 1 Aug 2026
  • Clinical genitourinary cancer
Real-World Efficacy and Safety of Frontline Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Study and Review of the Literature.
  • 1 Aug 2026
  • Clinical genitourinary cancer
Toward Interpretable Machine Learning Models for Grading Prostate Cancer: A Multicenter Development and Validation Study.
  • 1 Aug 2026
  • Clinical genitourinary cancer
Robust Meta-Analysis of a Clinical Cell-Cycle Risk (CCR) Score Demonstrates Broadly Applicable Metastasis and Disease-Specific Mortality Risk Stratification in Men With Localized Prostate Cancer.
  • 1 Aug 2026
  • Clinical genitourinary cancer

FAQs on Clinical Genitourinary Cancer